Clinical Trials Browser

Mycosis Fungoides × Magnetic Resonance Spectroscopy × Lymphoid × Clear all

Mycosis Fungoides, Sezary Syndrome

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT06508463 2026-04-13

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Phase 1 Recruiting

21 enrolled

Lymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Phase 1/2 Terminated

8 enrolled 8 charts

Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

17 enrolled

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT00769288 2014-01-07

FAU in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed

12 enrolled

DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT00504205 2013-08-02

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

Phase NA Terminated

30 enrolled

DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

Clinical Trials

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

FAU in Treating Patients With Advanced Solid Tumors or Lymphoma

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma